ASX Quarterlies: From fintech to biotech, these small caps have delivered strong results for shareholders
It’s quarter season as the ASX market announcement page becomes increasingly inundated with lodgers.
The last day for companies to submit reports is the last working day of the first month following the previous quarter. If they don’t, they risk suspension (and subsequent panic and anger from shareholders).
Here are some of the reports that have caught our eye today.
Fintech MONEYME grew its revenues in FY22 to around $138m, with 4Q22 revenues >$55m. Gross accounts receivable for FY22 also increased to $1.4 billion, up 366% pcp.
Q4 gross revenue of $55 million was up 190% vs. pcp, and was much higher than the $35 million achieved in Q3.
Contract income for the quarter was $398m, up 306% on pcp, while loan assignments were $334m (of which 49% consists of secured asset financing), up 107% on pcp.
MONEYME’s closing average Equifax score increased to 704 against 650 in the same period last year.
Net loss on the books narrowed to 3%, compared to 5% in the fourth quarter of FY21.
With strong unit economics and economies of scale delivered, MONEYME said its shifting focus in the near term from high to more moderate growth will drive an earlier realization of cash returns.
The company now expects to deliver over $200 million in revenue for FY23.
Clayton Howes, MONEYME’s CEO said:
“MONEYME’s agility in evolving market conditions is part of what makes MONEYME a strong consumer lender.
“Our innovation-led business model gives us the advantage to recalibrate quickly to support the ongoing delivery of profitable returns.”
The clinical-stage oncology company reported a strong cash balance of $12.27 million for the June quarter, supporting its many cancer programs.
Costs for the quarter included ongoing clinical trials and manufacturing for PTX-100 and PTX-200, development of the OmniCAR platform, as well as the recently unveiled high-throughput cell therapy technology.
Although no results have been released on the OmniCAR programs, the company says steady progress has been made across the programs, including in vivo studies.
Total cash flows for the quarter were broadly in line with the previous quarter at $1.2 million, with $0.5 million invested in R&D activities in Australia and the United States.
The PTX-200 study has now expanded its cohort after a fourth complete remission.
Combined with chemotherapy (cytarabine) in patients with relapsed and refractory acute myeloid leukemia (AML), the study of PTX-200 reported that another patient had complete remission of the disease at the dose of 45 mg/m2.
In parallel, PTX-100 has also expanded its study on T-cell lymphoma patients.
Patients with T-cell lymphomas (TCL) are constantly being registered and treated in the expansion cohort under the leadership of Professor Miles Prince.
Prescient expects the recruitment to remain on track for completion by the end of calendar 2022.
The developer of security, surveillance and alerting solutions has delivered FY22 revenue of $5.83 million (up 11% on pcp), of which $3.33 million (57%) is classified as recurring revenue.
For Q4, Spectur delivered flat revenue of $1.43 million, including $491k in the month of June.
Recurring revenue for the year (consisting of subscriptions and rentals) grew to $3.33 million, with recurring annual revenue in June equaling an annualized run rate of $3.76 million.
Total available funding at the end of June 2022 was $1.43m, with net cash used in operating activities in Q4 FY22 of $248k.
The company’s unweighted sales pipeline grew to $10.2 million (weighted $3.55 million), underpinning expectations for continued growth into FY23.
During the quarter, Spectur successfully placed $1.86 million in July, and a securities purchase plan (SPP) to raise $500k is now open to shareholders.
“We have a clear strategic path and, with recent funding activity, the balance to execute,” said Spectur’s chief executive, Gerard Dyson.
“It is our expectation that the work we will do to build the sales and marketing resources, globalize our technology and plan for further expansion internationally will drive the inflection point in sales, revenue and ultimately profitability and cash generation.”
Spacetalk achieved total revenue of $4.1 million, an increase of 40.9% on pcp.
Total revenue for fiscal 2022 was $20.7 million, an increase of 37.1% over pcp. This is the first time the company’s annual revenue has exceeded $20 million.
Wearables revenue for the three months to the end of June 2022 was $3.5 million, up 51.5% from the previous corresponding quarter.
4QFY22 Annualized Recurring Revenue (ARR) from Spacetalk App monthly subscriptions was $3.8 million, up 40.7% compared to pcp.
Wearables sales for the quarter were achieved with marketing expenses of $0.5 million compared to $0.3 million in pcp.
Revenue for the MGM Schools Business for the three months to June 30, 2022 was $0.6 million, up 4.9% pcp.
The MGM Schools Business continues to be a strong net cash flow contributor for the Company.
Share prices today:
At Stockhead, we tell it like it is. While MONEYME, Spectur and Prescient are Stockhead advertisers, they did not sponsor this article.
